Lilly’s Mounjaro Adds a Heart Claim, Deepening Its Blockbuster Lead

The FDA has expanded the US label for Eli Lilly’s Mounjaro (tirzepatide) to include reducing cardiovascular risk in adults with type 2 diabetes — a milestone for the drug and for its dual GIP/GLP-1 mechanism.

The evidence, and why the comparator matters

The expansion is backed by SURPASS-CVOT, in which Mounjaro reduced the combined risk of cardiovascular death, heart attack or stroke by 8% compared with Trulicity (dulaglutide).

An 8% relative reduction reads as unimpressive until the comparison is understood. Most cardiovascular outcomes trials test a drug against placebo, so the reduction reflects the whole benefit of treating versus not treating.

SURPASS-CVOT did something harder. Dulaglutide is an established GLP-1 drug that had already demonstrated cardiovascular benefit in its own placebo-controlled trial. So the 8% is not the benefit of tirzepatide versus nothing — it is the additional benefit over a drug already reducing cardiovascular events.

Beating an active comparator that works is substantially more demanding than beating placebo, and an 8% margin on top of an established benefit is a different achievement from an 8% margin against no treatment.

What makes tirzepatide mechanistically different

Most drugs in this class target the GLP-1 receptor alone. Tirzepatide targets both GLP-1 and GIP receptors — two gut hormones released after eating that influence insulin secretion, appetite and metabolism.

GIP’s contribution was uncertain for years; earlier work suggested it might be unhelpful or even counterproductive in obesity. Adding it turned out to produce greater glucose lowering and weight loss than GLP-1 alone, and this approval makes tirzepatide the first GIP/GLP-1-targeting therapy approved for a cardiovascular indication in the US.

Why cardiovascular claims matter in diabetes

“Mitigating cardiovascular risk is essential and can be overlooked” in type 2 diabetes, said Duke endocrinologist David D’Alessio.

That understates a central fact of the disease: heart disease is the leading cause of death in type 2 diabetes. Glucose control is the visible target — the number patients and clinicians track — but the reason it matters is largely the complications it drives, and cardiovascular disease is the biggest of them.

Historically, diabetes drugs were approved on glucose lowering alone, with cardiovascular benefit assumed. That assumption proved unsafe when some agents lowered glucose while worsening cardiovascular outcomes, which is why dedicated outcomes trials became a regulatory expectation. A drug with a demonstrated cardiovascular claim is therefore making a qualitatively different statement from one that merely lowers HbA1c well.

The commercial position

Mounjaro recently became the world’s top-selling prescription medicine, with Q2 2026 sales of $9.9 billion, up 91% year over year.

Adding a cardiovascular claim strengthens the case with both physicians and payers. For payers particularly, this is the argument that matters: a drug preventing heart attacks and strokes offsets some of its cost against expensive acute events, which is a stronger basis for coverage than weight loss alone.

Novo Nordisk’s Wegovy, a GLP-1-only drug, won a similar approval in 2024, so this is competitive catch-up as much as differentiation — though in a different population.

What the label does and does not cover

Worth being precise: this expansion covers cardiovascular risk reduction in adults with type 2 diabetes. It is not a claim about people with obesity but without diabetes, who represent a large share of the drug’s use under its obesity branding.

That distinction matters clinically and commercially. Extending a cardiovascular claim into the obesity population without diabetes would require its own evidence, and would be considerably more valuable given the size of that market.

The competitive dynamic

The GLP-1 market is projected to exceed $125 billion by 2033, and competition is intensifying — oral formulations, next-generation multi-receptor agonists, and eventual generic entry all loom.

In that environment, accumulated indications function as a defence. A drug with strong glucose control, substantial weight loss and proven cardiovascular benefit is harder for a newcomer to displace, because a competitor must match not just the primary effect but the accumulated evidence supporting each additional claim — which takes years and large trials.

The caveats

An 8% relative reduction remains a modest margin, and the absolute difference in events between two active treatments will be smaller still. The trial establishes tirzepatide is at least as good as, and somewhat better than, an established alternative — not that it is transformative relative to existing options.

Cost also remains the dominant practical constraint. A cardiovascular claim strengthens the coverage argument without resolving the affordability problem that determines who actually receives these drugs. Business and regulatory news, not medical or investment advice.